+ Watch PLX
on My Watchlist
A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.
Based on the news on the street and the performance of the stock at these levels, this company has the potential of reaching 2000% in the next 4 years. This stock has found a bottom like AKS did several years ago which reached a high of 70+ before it cratered. This is a 'Just about Perfect' time to start to buy this stock!
I agree with above now. Perfect time now to get loaded up ( deja vu!), almost 3 years later. Market cap of 500m . Was 2 billion in 2007 without any drugs approved by FDA.Pfizer is backing the company. Protalix now has a CRL and PDUFA date in Feb, marketing agreement with Pfizer. Pfizer will also give milestone payments ( $50million on FDA approval). Drug is already being used ( special access granted after Genentech's Cerebrozyme shortage). No chance of viral contamination in Protalix drug as it is a plant cell based production ( unlike its competition)
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions